Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology company focused on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (âSNMâ) solutions. SNM therapy is primarily used to treat patients with overactive bladder (âOABâ), fecal incontinence (âFIâ) and urinary retention (âURâ). Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR. Source
No articles found.
We are a fully integrated biopharmaceutical company focused on the development and...
We are a fully integrated biopharmaceutical com...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
The recognized global leader in neuromodulation devices to treat blindness, the co...
The recognized global leader in neuromodulation...
MiMedxŽ is a biopharmaceutical company developing, manufacturing and marketing reg...
MiMedxŽ is a biopharmaceutical company developi...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Novocure is a global oncology company working to extend survival in some of the mo...
Novocure is a global oncology company working t...
Join the National Investor Network and get the latest information with your interests in mind.